smithklin beckman corp said and sign final agreement develop and market new cardiovascular medicin discov boehring under agreement smithklin said will have respons for develop product both partner will market product and abroad initi smithklin said compani will concentr clinic develop and market carvedilol which compound treat mild moder hypertens and angina applic for market approv carvedilol was submit west germani last decemb smithklin said applic expect european market this year and submiss food and drug administr project for 1990 said work also underway thromboxan receptor antagonist compound which could use acceler disolut blood clot and prevent blod clot from occur heart attack well arteri diseas compani said two these compound clinic evalu europ and reuter 